IQVIA Honored as a Leader in Generative AI by Everest Group

On April 23, 2025, IQVIA (NYSE: IQV), a prominent provider of clinical research services, commercial insights, and healthcare intelligence, announced that it has been named a "front-runner generative AI leader" in the life sciences industry by the Everest Group, a global independent research and analysis firm. This recognition highlights IQVIA's robust generative AI capabilities and positions it as a key player in the ongoing transformation of healthcare through technology.

The Everest Group's report, titled “AI-deas to Action: Operationalizing Generative AI in Life Sciences,” evaluated 15 carefully selected organizations, including broad-based AI companies, clinical research organizations (CROs), and specialized life sciences firms. IQVIA emerged as the sole clinical research organization to achieve the highest ranking of "front-runner," underscoring its unique commitment to integrating AI into its operations. Notably, IQVIA is also the only CRO with a dedicated technology business unit to receive this prestigious designation.

Aastha Malik, practice director at Everest Group, emphasized IQVIA's thoughtful approach to generative AI strategy. "By striving for operational excellence and emphasizing the need for responsible AI governance, IQVIA is taking a thoughtful approach to its generative AI strategy, scaling select use cases from concept to deployment to maximize value across the stages of the product life cycle," Malik stated. This commitment reflects IQVIA's focus on delivering high-quality services while ensuring ethical AI governance.

The Everest Group report ranked IQVIA among five front-runners, noting its leadership in strategic integrations of generative AI capabilities throughout various research and development stages. IQVIA's Healthcare-grade AI® solutions are designed to enhance clinical trial design, refine product commercialization strategies, and provide deeper insights into provider engagement and market access. These innovations represent a significant advancement in how life sciences organizations can leverage AI to improve patient outcomes and operational efficiency.

Harietta Eleftherochorinou, vice president of AI Strategy and Operations at IQVIA, articulated the challenges and opportunities that come with AI innovation in the healthcare sector. "Today’s life sciences and healthcare organizations are looking to balance AI innovation with continuous service delivery at high standards, striving for operational excellence," Eleftherochorinou said. She emphasized the importance of effective governance in AI implementation to ensure real-world value for customers and their patients.

IQVIA's reputation for driving innovation and operational efficiency was further solidified earlier this year when its IQVIA AI Assistant received the PM360 Innovation Award in the AI Category. This interactive tool is designed to revolutionize insight generation within the healthcare and life sciences industries, showcasing IQVIA's ongoing commitment to harnessing technology for better healthcare solutions.

Everest Group is a leading global research firm that assists business leaders in navigating complex market challenges. Through contextualized problem-solving, it helps clients maximize operational and financial performance.

On the other hand, IQVIA's portfolio of solutions, powered by IQVIA Connected Intelligence™, aims to deliver actionable insights and services built on high-quality health data, advanced analytics, and extensive domain expertise. With approximately 88,000 employees worldwide, IQVIA is dedicated to enhancing the development and commercialization of innovative medical treatments, ultimately improving patient outcomes and population health globally.

This recent recognition from Everest Group positions IQVIA at the forefront of generative AI innovation in life sciences, paving the way for continued advancements in the integration of technology and healthcare.